| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018536217 |
| P356 | DOI | 10.1007/S40265-014-0271-Z |
| P698 | PubMed publication ID | 25060982 |
| P5875 | ResearchGate publication ID | 264248080 |
| P2093 | author name string | Mark Sanford | |
| P2860 | cites work | Anticholinergics for urinary symptoms in multiple sclerosis | Q24241666 |
| Adverse events after botulinum A toxin injection for neurogenic voiding disorders | Q36059392 | ||
| Pharmacology and immunology of botulinum neurotoxins | Q36170659 | ||
| New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. | Q36789948 | ||
| Neurogenic bladder in spinal cord injury | Q36837718 | ||
| Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety | Q37242597 | ||
| Update on the management of overactive bladder: patient considerations and adherence | Q37283704 | ||
| OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology | Q37299990 | ||
| A UK consensus on the management of the bladder in multiple sclerosis | Q37446501 | ||
| OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity | Q37536741 | ||
| Bladder symptoms in multiple sclerosis: a review of pathophysiology and management | Q37766886 | ||
| Neural control of the bladder: recent advances and neurologic implications | Q37809681 | ||
| Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity | Q37817727 | ||
| Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. | Q37835086 | ||
| Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management | Q37941525 | ||
| Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overview | Q37951376 | ||
| The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review | Q38034119 | ||
| Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications | Q42926647 | ||
| Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor | Q45330026 | ||
| OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. | Q45907261 | ||
| Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | Q46349100 | ||
| Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity | Q46586297 | ||
| Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection | Q46601229 | ||
| Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 | ||
| OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity | Q48303526 | ||
| Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity | Q48389748 | ||
| Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 | ||
| Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries | Q48638350 | ||
| Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. | Q49073287 | ||
| Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. | Q51458905 | ||
| Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. | Q53155089 | ||
| Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. | Q53194715 | ||
| Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. | Q53194798 | ||
| Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. | Q54465091 | ||
| Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections | Q81096770 | ||
| Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 | ||
| Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity | Q83335226 | ||
| Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis | Q83445672 | ||
| Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats | Q85015149 | ||
| Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis | Q95480937 | ||
| P433 | issue | 14 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| urinary incontinence | Q281490 | ||
| botulinum toxin type A | Q4095199 | ||
| P304 | page(s) | 1659-1672 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury | |
| P478 | volume | 74 |
| Q91726372 | Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study |
| Q55239076 | Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. |
| Q40936665 | Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury |
| Q36115240 | Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study |
Search more.